Bidding for Biogen’s Biosimilars – Intas Best Placed Over Samsung & Dr. Reddy’s?

A bidding war is reportedly heating up for Biogen’s biosimilars portfolio, with three major pharmaceutical companies reportedly offering around $1 billion for the business unit – Samsung Bioepis, India’s Dr. Reddy’s Laboratories, and Intas Pharmaceuticals. Of the three, Samsung and Intas may be placed to gain the maximum from the acquisition. Biogen’s biosimilars division focuses […]

Exit mobile version